Rotaxane-based propeptides: protection and enzymatic release of a bioactive pentapeptide

Angewandte Chemie - International Edition

Volumn 48, Issue 35, 2009, Pages 6443-6447

  Fernandes, Anthony ^a   Viterisi, Aurélien ^a   Coutrot, Frédéric ^a   Potok, Stéphanie ^a   Leigh, David A ^a   Aucagne, Vincent ^b   Papot, Sébastien ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^c UNIVERSITÉ DE POITIERS   (France)

Author keywords

Delivery systems; Peptides; Prodrugs; Rotaxanes; Supramolecular chemistry

Indexed keywords

DELIVERY SYSTEMS; GLYCOSIDASES; HUMAN PLASMAS; MACROCYCLES; POOR STABILITY; PRODRUGS; PROPEPTIDES; ROTAXANES;

AMINES; CARBOHYDRATES; MACROMOLECULES; PEPTIDES; SUPRAMOLECULAR CHEMISTRY;

PLASMA STABILITY;

PEPTIDE; PRODRUG; ROTAXANE;

ARTICLE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG STABILITY; METABOLISM;

DELAYED-ACTION PREPARATIONS; DRUG STABILITY; PEPTIDES; PRODRUGS; ROTAXANES;

EID: 70349913585     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200903215     Document Type: Article

References (69)

1. a) T. D. Nguyen, H.-R. Tseng, P. C. Celestre, A. H. Flood, Y. Liu, J. F. Stoddart, J. I. Zink, Proc. Natl. Acad. Sci. USA 2005,102, 10029-10034;
2. b) K. C-F. Leung, T.D Nguyen, J. F. Stoddart, J. I. Zink, Chem. Mater. 2006,18, 5919-5928;
3. c) T. D. Nguyen, K. C.-F. Leung, M. Liong, C. D. Pentecost, I. F. Stoddart, J. I. Zink, Org. Lett. 2006, 5, 3363-3366;
4. d) T. D. Nguyen, Y. Liu, S. Saha, K. C.-F. Leung, J. F. Stoddart, J. I. Zink, J. Am. Chem. Soc. 2007,129, 626-634;
5. e) T. D. Nguyen, K. C.-F. Leung, M. Liong, Y Liu, J. F. Stoddart, J. L. Zink, Adv. Fund. Mater. 2007, 17, 2101-2110;
6. f) S. Angelos, Y.-W. Yang, K. Patel, I. F. Stoddart, J. I. Zink, Angew. Chem. 2008, 120, 2254-2258;
7. Angew. Chem. Int. Ed. 2008, 47, 2222-2226;
8. g) K. Patel, S. Angelos, W. R. Ditchel, A. Coskun, Y-W Yang, J. I. Zink, I. F. Stoddart, J. Am.
9. Chem. Soc. 2008, 130, 2382-2383;
10. h) D. P. Ferris, Y-L. Zhao, N M. Khashab, H. A. Khatib, J. F. Stoddart, J. I. Zink, J. Am. Chem. Soc. 2009, 131, 1686-1688.
11. a) E. Arunkumar, C. C. Forbes, B. C. Noll, B. D. Smith, J. Am. Chem. Soc. 2005, 127, 3288-3289;
12. b) E. Arunkumar, N. Fu, B. D. Smith, Chem. Eur. J 2006,12, 4684-4690;
13. c) J. R. Johnson, N. Fu, E. Arunkumar, W. M. Leevy, S. T. Gammon, D. PiwnicaWorms, B.D. Smith, Angew. Chem. 2007, 119, 5624-5627;
14. Angew. Chem. Int. Ed. 2007, 46, 5528-5531;
15. d) J. J. Gassensmith, E. Arunkumar, L. Barr, J. M. Baumes, K. M. DiVittorio, J. R. Johnson, B. C. Noll, B. D. Smith, J. Am. Chem. Soc. 2007, 129, 15054-15059.
16. A. G. Cheetham, M. G. Hutchings, T. D. W. Claridge, H. L. Anderson, Angew. Chem. 2006, 118, 1626-1629;
17. Angew. Chem. Int. Ed. 2006, 45, 1596-1599.
18. a) V. Dvornikovs, B. E. House, M. Kaetzel, J. R. Dedman, D. B. Smithrud, J. Am. Chem. Soc. 2003,125,8290-8301;
19. b) X. Bao, J. Jsaacsohn, A. F. Drew, D. B. Smithrud, J. Am. Chem. Soc. 2006, 125, 12229-12238;
20. c) J. Zhu, B. E. House, E. Fleck, J. Isaacsohn, A. F. Drew, D. B. Smithrud, Bioorg. Med. Chem. Lett. 2007,17, 5058-5062;
21. d) X. Wang, X. Bao, M. McFarland-Mancini, I. Isaacsohn, A. F. Drew, D. B. Smithrud, J. Am. Chem. Soc. 2007, 129, 7284-7293;
22. e) J. Zhu, M. McFarland-Mancini, A. F. Drew, D.B. Smithrud, Bioorg. Med. Chem. Lett. 2009, 19, 520-523.
23. a) T. Ooya, N. Yui, Crit. Rev. Ther. Drug Carrier Syst. 1999,16, 289-330;
24. b) T. Ooya, N. Yui, J. Controlled Release 1999, 58, 251-269;
25. c) T. Ooya, K. Arizono, N. Yui, Polym. Adv. Technol. 2000, 11, 642-651;
26. d) M. Eguchi, T. Ooya, N. Yui, J. Controlled Release 2004, 96, 301-307.
27. a) D. A. Leigh, A. Murphy, J. P. Smart, A. M. Z. Slawin, Angew. Chem. 1997, 109, 752-756;
28. Angew. Chem. Int. Ed. Engl. 1997, 36, 728-732;
29. b) G. W. H. Wurpel, A.M. Brouwer, I. H. M. van Stokkum, A. Farran, D. A. Leigh, J. Am. Chem. Soc. 2001, 123, 11327-11328;
30. c) G. Brancato, F. Coutrot, D. A. Leigh, A. Murphy, I. K. Y. Wong, F. Zerbetto, Proc. Natl. Acad. Sci. USA 2002, 99, 4967-4971;
31. d) M. Asakawa, G. Brancato, M. Fanti, D. A. Leigh, T. Shimizu, A. M. Z. Slawin, J. K. Y. Wong, F. Zerbetto, S. Zhang, J. Am. Chem. Soc. 2002, 124, 2939-2950;
32. e) T. Da Ros, D. M. Guldi, A. Farran Morales, D. A. Leigh, M. Prato, R. Turco, Org. Lett. 2003, 5, 689-691;
33. f) G. Bottari, D. A. Leigh, E. M. Pérez, J. Am. Chem. Soc. 2003, 125, 13360-13361;
34. g) J. S. Hannam, S. M. Lacy, D. A. Leigh, C. G. Saiz, A. M. Z. Slawin, S. G. Stitchell, Angew. Chem. 2004, 116, 3322-3326;
35. Angew. Chem. Int. Ed. 2004, 43, 3260-3264;
36. h) D.. A. Leigh, M. Á.F. Morales, E. M. Pérez, J. K. Y. Wong, C.G. Saiz, A. M. Z. Slawin, A. J. Carmichael, D.M. Haddleton, A.M. Brouwer, W. J. Buma, G. W. H. Wurpel, S. León, F. Zerbetto, Angew. Chem. 2005, 117, 3122-3127;
37. Angew. Chem. Int. Ed. 2005, 44, 3062-3067.
38. Peptide-Based Drug Design Methods in Molecular Biology, Vol.494 (Ed.: L. Otvos), Humana Press, New York, 2008.
39. This is likely a result of the folding of the thread through strong intramolecular hydrogen bonding in the nonpolar solvents used to promote hydrogen bond-template rotaxane formation. Yields of rotaxanes from related pentapeptide threads attempted in our laboratory were typically less than 1 %.
40. P. Garner, J. U. Yoo, Tetrahedron Lett. 1993, 34, 1275-1278.
41. a) S. J. Rowan, I. F. Stoddart, J. Am. Chem. Soc. 2000,122,164-165;
42. b) D. W. Zehnder, D. B. Smithrud, Org. Lett. 2001, 3, 2485-2487;
43. c) S.-H. Chiu, S. J. Rowan, S. J. Cantrill, J. F. Stoddart, A. J. P. White, D. J. Williams, Chem. Eur. J 2002, 5, 5170-5183;
44. d) T. J. Kidd, T. J. A. Loontjens, D. A. Leigh, J. K. Y. Wong, Angew. Chem. 2003, 115, 3501-3505;
45. Angew. Chem. Int. Ed. 2003, 42, 3379-3383;
46. e) O. Š. Miljanić, W. R. Dichtel, I. Aprahamian, R. D. Rohde, H. D. Agnew, J. R. Heath, J. F. Stoddart, QSAR Comb. Sci. 2007, 26, 1165-1174;
47. f) J. M. Spruell, W. R. Dichtel, J. R. Heath, J. F. Stoddart, Chem. Eur. J 2008, 14, 4168-4177.
48. a) I. S. Zagon, P. J. McLaughlin, Neuropeptides 2003, 37, 79-88;
49. b) J. Fichna, A. Janecka, Cancer Metastasis Rev. 2004, 23, 351 -366;
50. c) I. S. Zagon, P. J. McLaughlin, Neuropeptides 2005, 39, 495-505;
51. d) I. S. Zagon, K. A. Rahn, P. J. McLaughlin, Neuropeptides 2007, 41, 441-452;
52. e)F. Cheng, I. S. Zagon, M. F. Verderame, P. J. McLaughlin, Cancer Res. 2007, 67, 10511-10518;
53. f) F. Cheng, P. J. McLaughlin, M. F. Verderame, J. S. Zagon, Mol. Biol. Cell 2009, 20, 319-327.
54. a) H. Cheng, X. Cao, M. Xian, L. Fang, T. B. Cai, J. J. Ji, J. B. Tunac, D. Sun, P. G. Wang, J. Med. Chem. 2005, 48, 645-652;
55. b) L. F. Tietze, F. Major, I. Schuberth, Angew. Chem. 2006,118, 6724-6727;
56. Angew. Chem. Int. Ed. 2006, 45, 6574-6577;
57. c) A. Kamal, V. Tekumalla, A. Krishnan, M. Pal-Bhadra, U. Bhadra, ChemMedChem 2008, 3, 794-802.
58. a) P. D. Senter, C. J. Springer, Adv. Drug Delivery Rev. 2001, 53, 247-264;
59. b) K. D. Bagshawe, Expert Rev. Anticancer Ther. 2006, 6, 1421-1431.
60. a) S. Papot, I. Tranoy, F. Tillequin, J.-C. Florent, J.-P. Gesson, Curr. Med. Chem. Anti-Cancer Agents 2002, 2, 155-185;
61. b) I. Tranoy-Opalinski, A. Fernandes, M. Thomas, J.-P. Gesson, S. Papot, Anti-Cancer Agents Med. Chem. 2008, 5, 618-637.
62. a) F. Coutrot, E. Busseron, J.-L. Montero, Org. Lett. 2008,10, 753-756;
63. b)F. Coutrot, C. Romuald, E. Busseron, Org. Lett. 2008, 10, 3741-3744;
64. c) F. Coutrot, E. Busseron, Chem. Eur. J. 2008, 14, 4784-4787;
65. d) F. Coutrot, E. Busseron, Chem. Eur. J. 2009, 15, 5186-5190.
66. a) C. Gros, B. Giros, J. C. Schwartz, Biochemistry 1985, 24, 2179-2185;
67. b) H. Terashima, N. Bunnett, J .Gastroenterol. 1995, 30, 696-704.
68. J. Lanzillo, J. Stevens, Y. Dasarathy, H. Yotsumoto, B. Fanburg, J. Biol. Chem. 1985, 260,14938-14944.
69. Intermediates 8 and 9 are only stable for a few minutes at pH 7 at 37°C However, they survive for hours at pH2 at room temperature (the equilibrium between the phenol and phenolate forms is shifted toward the phenol and elimination occurs only slowly). In the gal-catalyzed reactions, aliquots were withdrawn from the reaction medium and diluted with a solution of trifluoroacetic acid (to pH 2) before being injected into the HPLC apparatus with the mobile phase buffered at pH 2 (see the Supporting Information).